AD	ı	

Award Number: DAMD17-00-1-0205

TITLE: A Novel Role for Integrin-Linked Kinase in Breast Cancer

PRINCIPAL INVESTIGATOR: Pratima Karnik, Ph.D.

CONTRACTING ORGANIZATION: The Cleveland Clinic Foundation

Cleveland, Ohio 44195

REPORT DATE: September 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

## REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Burdent, Panerwork Reduction Project (0704-0188), Washington, DC 20503

I Management and budget, Faperwork Reduction Froje	3CI (0704-0100), Washington, DC 20303			
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND	DATES COVERE	D
	September 2002	Annual (1 Sep	,	
4. TITLE AND SUBTITLE			5. FUNDING N	
A Novel Role for Int	egrin-Linked Kina.	se in Breast	DAMD17-00-	-1-0205
Cancer				
6. AUTHOR(S)				
Pratima Karnik, Ph.D.				
Placima Raimik, Fin.				
7. PERFORMING ORGANIZATION NAT	8. PERFORMING ORGANIZATION			
			REPORT NUMBER	
The Cleveland Clinic Foundation				
Cleveland, Ohio 44195				
E-MAIL: karnikp@ccf.org				
	10. SPONSORING / MONITORING AGENCY REPORT NUMBER			
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)				
U.S. Army Medical Research and M	Nateriel Command		AGENOTIN	LI OIII HOMBEIL
Fort Detrick, Maryland 21702-501				
1 of Bottlok, Maryland 21702 301	-			
11. SUPPLEMENTARY NOTES		***************************************	<u></u>	
report contains color				
12a. DISTRIBUTION / AVAILABILITY STATEMENT				12b. DISTRIBUTION CODE
Approved for Public Release; Distribution Unlimited				
13. ABSTRACT (Maximum 200 Words	s <i>)</i>			
Allelic loss at the	short arm of chromosome	11 is one of the	most commo	n and
potent events in the prog	graccion and metastacis (	of breast cancer	Here we n	resent
evidence that the Integrir	Linked Kingse (IIK) c	ene mans to the	commonly d	leleted
chromosome 11p15.5 and	cuppresses malignent gro	with of human brea	st cancer cell	s hoth
in vitro and in vivo. ILK	is averaged in normal by	wan or naman orea	in metastatic	hreast
cancer cell lines or in adv	report opposes T	ransfection of wild	In inclastant	to the
cancer cell lines of in adv	Aniceu dieast cancers. I	tansiculum or wild	hair crowth	and
MDA-MB-435 mammary	/ carcinoma cens poter	iny suppressed t	nen Brown	anu

14. SUBJECT TERMS 15. NUMBER OF PAGES ILK, gene transfer, breast cancer, nude mouse assay 12 16. PRICE CODE 20. LIMITATION OF ABSTRACT 19. SECURITY CLASSIFICATION 17. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION OF THIS PAGE OF ABSTRACT OF REPORT Unclassified Unclassified

invasiveness in vitro, and reduced the cells' ability to induce tumors and metastasize in athymic mice. Conversely, expression of the ankyrin repeat or catalytic domain mutants of ILK failed to suppress the growth of these cells. Growth suppression by ILK is not due to apoptosis but is mediated by its ability to block cell cycle progression in the G1 phase. These findings directly demonstrate that ILK deficiency facilitates neoplastic growth and

suggest a novel role for the ILK gene in tumor suppression.

Unclassified

Unlimited

#### **FOREWORD**

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army. \_NA\_ Where copyrighted material is quoted, permission has been obtained to use such material. \_NA\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material. \_NA\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations. X\_In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985). For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Bratina Karnk PI-Signature Date September 12, 2002

# **Table of Contents**

Cover1
SF 2982
Foreword3
Table of Contents4
Introduction5
Body5
Conclusions6
Key Research Accomplishments7
Reportable Outcomes7
References8
Figure Legend10
Appendices1

#### A. INTRODUCTION

Genetic alterations that occur in breast cancer are believed to be of importance for initiation as well as progression of the disease. These genetic alterations lead to the loss or activation of a number of critical genes, such as those involved in cell proliferation, differentiation, apoptosis, and genetic stability. The genetic abnormalities most frequently observed in breast tumors are amplification of proto-oncogenes (MYC, ERBB2 and CCNDI), mutations of TP53, and loss of heterozygosity (LOH) on chromosomes 3p, 6q, 7q, 8p, 9p, 11, 13q, 17, 18q and 22q (1, 2). Metastatic phenotypes have been linked to such genes as NMEI (17q), CDHI (16q), BRMSI (11q), and KISSI (1q) (1, 3-5). LOH analyses have defined regions of deletion associated with metastasis on chromosomes 3p21, 15q14, 16q22 and 11p15 (2, 6)

Frequent genetic alterations on chromosome 11p15 suggest a crucial role for this region in breast (6, 7) and other adult (8-12) and childhood cancers (13-17). More recently, we have mapped two distinct regions on chromosome 11p15.5 that are subject to LOH during breast tumor progression and metastasis (6). LOH at region 1 correlated with tumors that contain ductal carcinoma *in situ* suggesting that the loss of a critical gene in this region may be responsible for early events in malignancy. LOH at region 2 correlated with a more aggressive tumor and an ominous outlook for the patient, such as aneuploidy, high S-phase fraction and the presence of metastasis in regional lymph nodes. Although considerable advances have been made in the fine-mapping of chromosome 11p15.5, the

tumor suppressor gene(s) encoded by this region have evaded identification.

Integrin-linked kinase (*ILK*) is an intriguing serine/threonine kinase that has been implicated in integrin-, growth-factor- and Wnt-signaling pathways (18). It binds to the cytoplasmic domains of β1 and β3 integrins and mediates the down-stream signaling events in integrin function (19). Interactions between integrins and their ligands are involved in the regulation of many cellular functions, including embryonic development, cell proliferation, tumor growth and the ability to metastasize (20). In *Drosophila*, the absence of *ILK* function causes defects similar to loss of integrin adhesion and *ILK* mutations cause embryonic lethality and defects in muscle attachment (21). Although *ILK* maps to the commonly deleted chromosome 11p, the potential of this gene in tumor suppression has not been established. We have therefore analyzed the effect of *ILK* expression on the *in vivo* tumor growth and invasion of human mammary carcinoma cells.

#### B. BODY:

#### 1. Results:

ILK suppresses tumor formation and metastasis in nude mice In the last progress report, we reported that we have transfected the ILK gene into the

metastatic breast cancer cell line MDA-MB-435 and have isolated four different clones that express different levels of ILK mRNA and protein. We are now testing these cells using a

nude mouse metastatic model.

The most stringent experimental test of neoplastic behavior is the ability of injected cells to form tumors in nude mice. Yet not all of the cellular growth properties commonly associated with the cellular state *in vitro* are required for neoplastic growth *in vivo* and vice versa. Therefore, loss of tumorigenecity under expression of *ILK in vivo* would be a critical test to substantiate the growth suppressor function of *ILK*. The mammary carcinoma cell line MDA-MB-435 forms tumors at the site of orthotopic injection, metastasizes in nude mice and closely resembles the course of human breast cancer (22). To investigate whether *ILK* expression affected tumor formation in nude mice, two different *ILK* transfectant clones (TR5-ILK and TR3-ILK) and two vector controls were inoculated into the subaxillary mammary fat pads of 4-6 week old athymic nude mice. Tumors were measured weekly thereafter to assess the growth rate. All MDA-MB-435 vector transfectants were already palpable 7 days after injection. Subsequently, the tumors of vector transfectants grew steadily attaining mean volumes of 3.0 cm³ (mean ± s.d.) at 15 weeks (Fig. 1A and B). In contrast, only 2 of 12 mice injected with ILK transfectants

developed tumors. The tumor growth of ILK transfectants was significantly slower than than that of control transfectants (P < 0.005, Fisher variance analysis). At sacrifice, (15 weeks) the ILK tumors reached a mean volume of only 0.45 cm³ (mean  $\pm$  s.d.) which was significantly smaller than control tumors (P < 0.001, Student's t-test). Vector transfected MDA-MB-435 cells developed an average of 12-24 lung metastases per mouse (Figure-1C). Additional tumor masses were present in central venous blood vessels, the diaphragm, and lymph nodes of vector transfectants (data not shown). In contrast, with the ILK transfectants, only one of the two animals that developed tumors showed a single metastatic colony in the lung. The presence of additional microscopic metastases in random lung sections was not observed by H&E staining (data not shown). These results clearly demonstrate that the expression of ILK in human MDA-MB-435 breast carcinoma cells significantly suppresses tumorigenecity and metastatic ability in athymic nude mice.

#### 2. Methods:

Tumorigenecity and Metastasis Assays

Cells (10<sup>6</sup>) were injected into the subaxillary mammary fat pads of 4-6 week-old female athymic nude mice Ncr nu/nu (10-12 mice/group; Taconic Labs, Germantown, NY) as described (52). Mice were maintained under the guidelines of NIH and the Cleveland Clinic Foundation. All protocols were approved and monitered by the the Institutional Animal Care and Use Committee. Food and water were provided *ad libitum*. Tumors were monitered weekly after inoculation. When the mean tumor diameter reached 1.0-1.3 cm, primary tumors were surgically removed under Ketaset-Rompun anesthetic. Mice were then maintained for an additional 4 weeks to allow further growth of lung metastases. After euthanasia, all organs were checked for metastases.

#### C. CONCLUSIONS:

In previous reports, we have provided evidence that ILK expression is down-regulated in primary breast tumors and in cell lines derived from metastatic breast tumors. We have shown that ILK overexpression inhibits the growth of the highly metastatic breast cancer cell line MDA-MB-435. In addition, ILK overexpression stimulates the levels of the growth suppressing integrin  $\alpha 5\beta 1$  and inhibits the levels of  $\alpha \nu \beta 3$ , a growth promoting integrin. These innovative studies suggest a novel role for ILK in the etiology of breast cancer. Functional studies in animal models were therefore undertaken to establish ILK as a metastasis suppressor gene. These studies are part of this year's report.

The present study reveals that expression of *ILK* potently suppresses *in vivo* tumorigenecity of the human mammary carcinoma cells. The MDA-MB-435 cells are a model for deficient *ILK* protein expression and transfection of the *ILK* gene is designed to restore this deficiency. As shown in the last year's report, the growth suppression activity requires a functional *ILK* protein, since expression of wild-type *ILK*, but not the ankyrin repeat or the catalytic domain mutants, resulted in growth suppression of MDA-MB-435 cells. These results suggest a possible role for *ILK* in the suppression of tumor growth and metastasis and directly implicate its loss in processes regulating the malignant phenotype in human breast cancer. *ILK* seems to play a dual role in the MDA-MB-435 model system. First, it regulates cell-cycle progression at the G1/S boundary and second, it modulates the levels of integrins, transmembrane receptors that have been shown to regulate growth, differentiation and invasiveness of cells. During this process, the neoplastic cells cease to proliferate and lose their ability to migrate through vitronectin membranes and to induce tumor growth and metastasis in nude mice (Figure-1).

### D. KEY RESEARCH ACCOMPLISHMENTS:

- Chromosome 11 harbors a breast cancer metastasis suppressor gene
- Integrin linked kinase (ILK) is a key candidate gene that maps to this region
- ILK expression is downregulated in breast carcinomas that metastasize
- ILK expression inhibits the growth of the metastatic breast cancer cell line MDA-MB-435 both in vitro and in vivo.

These data suggest that ILK functions as a metastasis suppressor gene in breast cancer

# E. REPORTABLE OUTCOMES:

• These results are being prepared as a manuscript for publication.

#### F. REFERENCES:

1. Driouch, K; Briffod, M; Bieche, I; Champeme, M.H; and Lidereau, R. Location of several putative genes possibly involved in human breast cancer progression. Cancer Res. 58: 2081-2086, 1998.

2. Bieche, I. and Lidereau, R., Genetic alterations in breast cancer.

Genes Chromosomes Cancer 14: 227-251, 1995.

3. Siitonen, S.M; Kononen, J.T; Helin, H.J; Rantala, I.S; Holli, K.A. and Isola, J.J. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer.

Am. J. Clin. Pathol. 105: 394-402, (1996).

4. Seraj, M.J; Samant, R.S; Verderame, M.F. and Welch, D.R. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 60: 2764-2769, 2000.

5. Lee, J.H; Miele, M.E; Hicks, D.J; Phillips, K.K; Trent, J.M; Weissman, B.E. and Welch, D.R. *KISS-1*, a novel human malignant melanoma metastasis-suppressor gene. J. Natl. Cancer Inst. 88: 1731-1737, 1996.

6. Karnik, P; Paris, M; Williams, B.R.G; Casey, G, Crowe, J and Chen P. Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Human Mol Genet 7: 895-903, 1998.

7. Karnik, P., Plummer, S., Casey, G., Myles, J., Tubbs, R., Crowe, J. and Williams, B.R.G. Microsatellite instability at a single locus (D11S988) on chromosome 11p15.5 as a late event in mammary tumorigenesis. Human Mol Genet 4: 1889-1894, 1995.

8. Fearon, E.R., Feinberg, A.P., Hamilton, S.H. and Vogelstein, B. Loss of genes on the short arm of chromosome 11 in bladder cancer.,

Nature 318: 377-380, 1985.

9. Viel, A., Giannini, F., Tumiotto, L., Sopracordevole, F., Visetin, M.C. and Biocchi, M. Chromosomal localisation of two putative 11p oncosuppressor genes involved in human ovarian tumours. Br. J. Cancer 66: 1030-1036, 1992.

10. Bepler, G. and Garcia-Blanco, M.A. Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small cell lung cancer. Proc. Natl. Acad. Sci., USA 91: 5513-5517, 1994.

11. Lothe, R.A., Fossa, S.D., Stenwig, A.E., Nakamura, Y., White, R. and Borresen, A.L. and Brogger, A. Loss of 3p or 11p alleles is associated with testicular cancer tumors. Genomics 5: 134-138, 1989.

Wang, H.P. and Rogler, C.E. Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas. Cytogenet.Cell Genet. 48: 72-78, 1988.

13. Karnik, P; Chen, P; Paris, M; Yeger, H. and Williams, B.R. Loss of heterozygosity at chromosome 11p15 in Wilms tumors: identification of two independent regions. Oncogene 17: 237-240, 1998.

14. Besnard-Guerin, C., Newsham, I., Winquist, R. and Cavenee, W.K. A common loss of heterozygosity in Wilms tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5. Hum. Genet., 97: 163-170, 1996.

15. Henry, I., Grandjouan, S., Couillin, P., Barichard, F., Huerre-Jeanpierre, C., Glaser, T., Philip, T., Lenoir, G., Chaussain, J.L. and Junien, C. Tumor specific loss of 11p15.5 alleles in del 11p13 Wilms tumor and in familial adrenocortical carcinoma. Proc. Natl. Acad. Sci. 86: 3247-3251, 1989.

16. Koufos, A., Hansen, M.F., Copeland, N.G., Jenkins, N.A., Lampkin, B.C. and Cavenee, W.K. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature *316*: 330-334, 1985.

- 17. Sotel-Avila, D. and Gooch, W.M. III. Neoplasms associated with the Beckwith-Wiedemann Syndrome. Perspect. Pediatr. Pathol. 3: 255-272, 1976.
- Dedhar, S; Williams, B. and Hannigan, G., Integrin-Linked Kinase (ILK): a regulator of integrin and growth-factor signalling.,
  Trends in Cell Biol. 9: 319-323. 1999
- 19. Hannigan, G.E; Leung-Hagesteijn, C; Fitz-Gibbon, L; Coppolino, M.G; Radeva, G; Filmus, J; Bell, J.C. and Dedhar, S. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379: 91-96, 1996.
- 20. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25, 1992.
- Zervas, C.G; Gregory, S.L and Brown, N.H. Drosophila Integrin-linked Kinase Is Required at Sites of Integrin Adhesiom to Link the Cytoskeleton to the Plasma Membrane. J. Cell Biol. *152*: 1007-1018, 2001.
- 22. Price, J.E; Polyzos, A; Zhang, R.D. & Daniels, L.M. Tumorigenecity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 50: 717-721, 1990.

#### FIGURE LEGEND:

Figure-1: (A) In vivo tumor growth of *ILK* transfected (-1) and vector transfected (-1) MDA-MB-435 cells in mammary fat pads of athymic nude mice. Each point represents the mean ± SE of tumors. (B) Five x 10<sup>5</sup> cells of *ILK* transfected (top panel) or vector transfected (bottom panel) MDA-MB-435 cells were injected s.c. into the mammary fat pad area below the nipple. Tumors were allowed to grow for 15 weeks at which time the mice were photographed and sacrificed. (C) Lung colony formation in athymic nude mice injected with vector transfected (VT) or *ILK* transfected (*ILK*) MDA-MB-435 cells. Bars represent S.E.

# **APPENDIX**



